Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $3 | $6 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $8 | $12 |
| Operating Income | -$4 | -$5 | -$8 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$3 | -$2 | $0 |
| Pre-Tax Income | -$8 | -$8 | -$10 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$10 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.12 | -0.15 | -0.19 |
| % Growth | -8.3% | 20% | 21.1% | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.19 |
| Weighted Avg Shares Out | 64 | 63 | 63 | 63 |
| Weighted Avg Shares Out Dil | 64 | 63 | 63 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$6 | -$8 | -$10 |
| % Margin | – | – | – | – |